Venus Medtech of Hangzhou partnered with Israel’s Keystone Heart to provide Keystone’s embolic protection device as part of Venus’ transcatheter heart valve replacement device. Keystone’s TriGuard Cerebral Embolic Protection device is designed to prevent brain damage from embolisms during cardiovascular surgeries. The two companies say studies show that 80% of the minimally invasive transaortic valve replacement (TAVR) procedures cause “covert” brain damage. Venus has filed for China approval of its TAVR system. If approved, it would be the first TAVR available in China.
